Latest research on Ustekinumab

CNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23 and presently undergoing clinical trials to determine its safety and effectiveness against the diseases Multiple Sclerosis, Psoriasis, and Psoriatic Arthritis.

Ustekinumab indications

The importance of this pathway in regulating pro-inflammatory effects seen in IBD is highlighted by the clinical improvement seen in patients with CD when treated with Ustekinumab, a monoclonal antibody directed against the p40 subunit shared by IL-12 and IL-23 [source, 2016]
Antibodies targeting the shared subunit IL-12p40 (Ustekinumab) have been shown to be more effective than placebo in treating patients with severe CD, especially those who failed to respond to anti-TNF therapy [37]. [source, 2015]
In a recent prospective, open label trial in AS patients, Ustekinumab was found to be effective in reducing of signs and symptoms in active AS. [source, 2015]
Based on this evidence, biologic therapy with Ustekinumab is an effective treatment for patients with refractory CD that is resistant to TNF-α antagonists. [source, 2015]
In adults, Ustekinumab has been shown to be effective and superior to etanercept for severe plaque psoriasis [41–43] and effective in adult patients with psoriatic arthritis who have had a previous failed TNFα inhibitor or are biologic-naive [44,45]. [source, 2015]
To bridge this gap of knowledge, we investigated the risk of ADA formation against Ustekinumab in a real world clinical setting and assessed its effect on therapeutic response in a Taiwanese population with psoriasis. [source, 2015]
By contrast, Ustekinumab is not associated to body weight increase in patients with chronic plaque psoriasis (36).The effects of anti-TNF therapy on insulin sensitivity is controversial (37, 38). [source, 2015]
Consistent with this classical mouse EAE-like paradigm, we observed a strong clinical effect of prophylactic treatment with Ustekinumab, a humanized monoclonal antibody (mAb) against the joint p40 subunit of interleukins (IL)-12 and -23 [8]. [source, 2015]
There are two emerging biologics, primarily developed in psoriasis and PsA, which seem to be effective not only in reducing inflammation but also in preventing bone formation in AS: Ustekinumab (UST), a compound targeting IL-12/IL-23 via the p40 subunit of both cytokines and the anti-IL-17 antibody secukinumab (SEC). [source, 2015]
Ustekinumab and Briakinumab are effective in psoriasis [161,162,163] and reduce both Th17 and Th1 cell numbers. [source, 2015]